Cristin-resultat-ID: 1117352
Sist endret: 19. februar 2015, 13:34
NVI-rapporteringsår: 2013
Resultat
Vitenskapelig artikkel
2014

The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study

Bidragsytere:
  • Karen Minde Fagerli
  • Elisabeth Lie
  • Desirée van der Heijde
  • Marte S. Heiberg
  • Åse Lexberg
  • Erik Rødevand
  • mfl.

Tidsskrift

Annals of the Rheumatic Diseases
ISSN 0003-4967
e-ISSN 1468-2060
NVI-nivå 2

Om resultatet

Vitenskapelig artikkel
Publiseringsår: 2014
Publisert online: 2013
Trykket: 2014
Volum: 73
Hefte: 1
Sider: 132 - 137

Importkilder

Scopus-ID: 2-s2.0-84889658974
Isi-ID: 000327835100024

Beskrivelse Beskrivelse

Tittel

The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study

Sammendrag

Background The role of co-medication with tumour necrosis factor inhibitors (TNFi) is well established in rheumatoid arthritis and ankylosing spondylitis. In psoriatic arthritis (PsA) there is little evidence available on this issue. Material and methods The analyses were based on data from the Norwegian longitudinal observational study on disease-modifying antirheumatic drugs (NOR-DMARD). Patients with PsA starting their first TNFi, either as monotherapy or with concomitant methotrexate (MTX), were selected. Baseline characteristics, responses after 3, 6 and 12 months, and drug survival were compared between those with and without MTX co-medication. A secondary analysis was performed on patients who had confirmed swollen joints at baseline. Cox regression was used to identify predictors of discontinuation. Results We included 440 patients, 170 receiving TNFi as monotherapy and 270 receiving concomitant MTX. The groups had similar baseline characteristics, except for number of swollen joints, which was higher in the concomitant MTX group. Responses were similar in the two groups in both analyses. Drug survival analyses revealed a borderline significant difference in favour of patients receiving co-medication (p=0.07), and this was most prominent for patients receiving infliximab (IFX) (p=0.01). In the Cox regression analysis lack of concomitant MTX and current smoking were independent predictors of discontinuation of TNFi. Conclusions We found similar responses to TNFi in patients with and without concomitant MTX, but drug survival was superior in patients receiving co-medication. The effect of MTX on drug survival was most prominent in patients receiving IFX. Smoking at baseline and use of TNFi as monotherapy were identified as independent predictors of drug discontinuation.

Bidragsytere

Karen Minde Fagerli

  • Tilknyttet:
    Forfatter
    ved Revmatologisk avdeling ved Diakonhjemmet sykehus

Elisabeth Lie

  • Tilknyttet:
    Forfatter
    ved Revmatologisk avdeling ved Diakonhjemmet sykehus

Desirée van der Heijde

  • Tilknyttet:
    Forfatter
    ved Revmatologisk avdeling ved Diakonhjemmet sykehus
  • Tilknyttet:
    Forfatter
    ved Universiteit Leiden

Marte Schrumpf Heiberg

Bidragsyterens navn vises på dette resultatet som Marte S. Heiberg
  • Tilknyttet:
    Forfatter
    ved Revmatologisk avdeling ved Diakonhjemmet sykehus

Åse Lexberg

  • Tilknyttet:
    Forfatter
    ved Drammen sykehus ved Vestre Viken HF
1 - 5 av 9 | Neste | Siste »